ABSTRACT
Objective:To observe and investigate the effects of real-time dynamic glucose monitoring, continuous subcutaneous insulin infusion combined with Carelink management software analysis on blood glucose control in newly diagnosed type 2 diabetic patients.Methods: 64 cases of patients with newly diagnosed with type 2 diabetes were selected from our hospital, and randomly divided into observation group and control group. The observation group were treated by real-time dynamic blood sugar monitoring and continuous subcutaneous insulin infusion joint Carelink management software analysis system, while the control group by continuous subcutaneous insulin infusion in combination with the real-time dynamic blood sugar monitoring. We compared serum C peptide, the rise of serum insulin levels and the decrease of blood glucose after ten days of treatment. At the same time, insulin resistance index (HOMA - IRI) and hypoglycemic events were compared between the two groups.Results: After treatment, the decrease range of blood glucose, postprandial blood glucose and HOMA-IRI in the observation group were significantly better than those in the control group (t=4.362,t=3.254,t=4.289; P<0.05). At the same time, the increase range of elevated fasting insulin, postprandial insulin, fasting C peptide and sugar after C peptide in the observation group were significantly better than those in the control group (t=3.712,t=4.115,t=3.831,t=3.889;P<0.05). The standard number of days of the blood glucose in the control group were significantly higher than those in the observation group (t=4.583,P<0.05).Conclusion: For patients with type 2 diabetes treated by real-time continuous glucose monitoring and continuous treatment of infusion combined with subcutaneous insulin Carelink management software can effectively reduce blood glucose, improve the insulin resistance of patients, reduce hypoglycemia and increased insulin sensitivity, meanwhile also can better protect the islet beta cell function.